Commentary

Podcast

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.

This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.

Related Videos
Related Content
Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma
December 20th 2024

Immune Checkpoint Inhibitor-Associated Nephritis: A Case of Nivolumab-Induced Acute Kidney Injury in a Patient with Urothelial Carcinoma

George DeMaagd, PharmD, BCPS Gregory Franz, MD, MPH Zachery Halford, PharmD, BCOP, BCPPS
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors
December 19th 2024

ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Nuclear Isotopes Could Help Address Challenges in Oncology Clinical Trials
December 17th 2024

Nuclear Isotopes Could Help Address Challenges in Oncology Clinical Trials

Deepika Khedekar, MPharm Prathamesh Khedekar, MSEE
Small Cell Lung Cancer Cells: These small, round cells in the lungs divide rapidly and are known for early metastasis, resulting in highly aggressive cancer.
December 17th 2024

Sacituzumab Govitecan-hziy Receives FDA Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer Treatment

Luke Halpern, Assistant Editor